Menkes Disease Market Set to Grow Through 2036 as First Approved Therapy Establishes Standard of Care and Gene Therapy Advances Preclinically

DelveInsight's "Menkes Disease - Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Menkes disease, historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

To know in detail about the Menkes disease market outlook, treatment uptake, and competitive landscape, click here: https://www.delveinsight.com/report-store/menkes-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Some of the Key Facts of the Menkes Disease Market Report
• The minimum birth prevalence for Menkes disease is believed to be 1 in 34,810 live male births, and potentially as high as 1 in 8,664 live male births based on recent genome-based ascertainment.
• Menkes disease is a devastating disorder, with death usually occurring between 6 months and 3 years of age.
• The US accounts for approximately 60% of the highest diagnosed prevalent cases of Menkes disease among the 7MM, with France recording the highest diagnosed prevalent cases among the EU4 and UK, followed by Germany.
• Menkes disease is more prevalent in males (~95%) than in females, with the incidence estimated at about 1 in 35,000 live male births.
• Copper histidinate (ZYCUBO) is the first and only FDA-approved therapy for Menkes disease, demonstrating a nearly 80% reduction in the risk of death compared to an untreated external control cohort.
• In March 2026, the US FDA announced the closing of the sale of the Rare Pediatric Disease Priority Review Voucher associated with copper histidinate's approval for USD 205 million.
• The Menkes disease pipeline remains limited, with AAV-ATP7A gene therapy - currently in preclinical development - representing the most notable investigational asset aimed at the underlying genetic defect.

Key Menkes Disease Companies
Sentynl Therapeutics, Cyprium Therapeutics, NICHD, and others.

Key Menkes Disease Therapies
Copper histidinate (ZYCUBO), AAV-ATP7A Gene Therapy, and others.
The Menkes disease market is expected to grow due to growing focus on rare disease research, the emergence of gene therapy approaches, and supportive regulatory incentives such as Orphan Drug Designation and Rare Pediatric Disease Designation. The continued advancement of AAV-ATP7A gene therapy is expected to further shape the competitive landscape over the forecast period.

Menkes Disease Overview
Menkes disease is a rare, X-linked recessive neurodegenerative disorder caused by mutations in the ATP7A gene, which encodes a copper-transporting ATPase essential for copper absorption and distribution. Defective ATP7A function results in:
• Systemic copper deficiency and impaired activity of copper-dependent enzymes
• Progressive neurological deterioration, connective tissue abnormalities, and developmental delay
• Seizures, hypotonia, failure to thrive, and characteristic sparse, brittle hair
The disease primarily affects males and typically presents during infancy; without treatment, it is often fatal in early childhood. Diagnosis relies on clinical presentation, low serum copper and ceruloplasmin levels, and genetic confirmation of ATP7A variants, with neuroimaging sometimes revealing cerebral atrophy and delayed myelination. Early diagnosis is critical, as therapeutic outcomes are highly dependent on treatment initiation before significant neurological damage occurs.

Get a free sample for the Menkes Disease Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/menkes-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Menkes Disease Market Segmentation
The Menkes disease market report proffers detailed analysis for the study period 2022-2036 segmented into:
• By Region/Geography: North America (US); Europe (Germany, France, Italy, Spain, and the UK); Asia-Pacific (Japan)
• By Drugs/Therapies
• By Epidemiology Segmentation: Total incident cases of Menkes disease, total prevalent cases of Menkes disease, total diagnosed prevalent cases of Menkes disease, total treated cases of Menkes disease

Download the report to understand which factors are driving Menkes disease market trends: https://www.delveinsight.com/report-store/menkes-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Menkes Disease Treatment Landscape
Current treatment is highly concentrated around correcting the underlying copper deficiency caused by ATP7A mutations:
• Copper histidinate (ZYCUBO) (Sentynl Therapeutics and Cyprium Therapeutics) is a subcutaneous injectable copper replacement therapy and the only FDA-approved, disease-specific treatment, delivering the greatest clinical benefit when initiated during the neonatal period, before neurological damage occurs.
• The therapy received US FDA Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease designations, along with EMA Orphan Drug Designation.
• Existing therapy does not fully correct the underlying genetic defect and has limited efficacy in patients diagnosed after symptom onset, leaving significant unmet need.
• AAV-ATP7A gene therapy (Cyprium Therapeutics, in collaboration with NICHD) is in preclinical development and has demonstrated the ability to rescue neurological phenotypes and improve survival in mouse models when co-administered with copper injections, aiming to address the root genetic cause rather than simply replacing deficient copper.

Discover more about therapies set to grab major Menkes disease market share: https://www.delveinsight.com/report-store/menkes-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Menkes Disease Market Strengths
• Copper histidinate's FDA approval establishes the first disease-specific standard of care, backed by strong survival benefit data and multiple regulatory designations.
• Growing regulatory incentives for rare and pediatric diseases continue to encourage investment in Menkes disease drug development.
• AAV-ATP7A gene therapy's preclinical rescue of neurological phenotypes signals genuine potential for a disease-modifying approach beyond copper supplementation.

Menkes Disease Market Opportunities
• The absence of a curative or fully disease-modifying therapy creates a significant opportunity for gene therapy approaches that address the underlying ATP7A defect.
• Expanded genetic testing, newborn screening, and next-generation sequencing adoption could enable earlier diagnosis, directly improving treatment efficacy and creating a larger addressable, early-intervention patient population.

Scope of the Menkes Disease Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025 | Base Year: 2026 | Forecast Period: 2026-2036
• Coverage: The US; Germany, France, Italy, Spain, and the UK; Japan
• Key Companies: Sentynl Therapeutics, Cyprium Therapeutics, NICHD, and others
• Key Therapies: Copper histidinate (ZYCUBO), AAV-ATP7A Gene Therapy, and others
• Market CAGR (Forecast Period): ~XX% (2026-2036)
• Analysis Includes: KOL views, SWOT analysis, reimbursement, conjoint analysis, unmet needs, market drivers and barriers, epidemiology patient burden

To know more about Menkes disease companies working in the market, visit: https://www.delveinsight.com/report-store/menkes-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Menkes Disease Market Report Introduction
2. Executive Summary for Menkes Disease
3. SWOT Analysis of Menkes Disease
4. Menkes Disease Market Overview at a Glance
5. Menkes Disease Disease Background and Overview
6. Menkes Disease Market Segmentation and Analysis
7. Regional Analysis of the Menkes Disease Market
8. Country-Specific Menkes Disease Market Analysis
9. Competitive Landscape and Key Company Profiles
10. Menkes Disease Unmet Needs
11. Menkes Disease Emerging Therapies and Pipeline
12. Menkes Disease Market Outlook
13. Menkes Disease Market Access and Reimbursement
14. Menkes Disease Market Drivers
15. Menkes Disease Market Barriers
16. Menkes Disease Recent Developments
17. Menkes Disease Appendix
18. Menkes Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma and diagnostics companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.